Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects

Inclusion Criteria

• Subjects were human immunodeficiency virus type 1 (HIV-1) positive, antiretroviral naïve adults at least 18 years of age with < 7 days of prior antiretroviral therapy.

• Subjects had plasma HIV-1 ribonucleic acid (RNA) levels >= 1,000 copies/mL at screening and were not acutely ill.

• Female subjects were nonpregnant and nonlactating.

Exclusion Criteria

• Subjects were excluded if screening laboratory analyses showed any of the following abnormal laboratory results:

• Presence of hepatitis B surface antigen (HBsAg)

• Hemoglobin <= 8.0 g/dL

• Absolute neutrophil count <= 750 cells/microliter

• Platelet count <= 50,000 per mL

• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >= 3.0 x Upper Limit of Normal (ULN)

• Calculated creatinine clearance < 50 mL/min